Literature DB >> 19326567

Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment.

Jarom E Hanson1, Elisabeth Birdsall, Kristi S Seferian, Marcus A Crosby, Kristen A Keefe, James W Gibb, Glen R Hanson, Annette E Fleckenstein.   

Abstract

Repeated high-dose methamphetamine administrations can cause persistent dopaminergic deficits. As individuals abusing methamphetamine are often exposed to recurrent high-dose administration, the impact of its repeated exposure merits investigation. Accordingly, rats were pretreated with repeated high-dose injections of methamphetamine, and subsequently "challenged" with the same neurotoxic regimen 7 or 30 days later. Results revealed that the initial methamphetamine treatment caused persistent deficits in striatal dopamine levels, dopamine transporter function, and vesicular monoamine transporter-2 function. The subsequent methamphetamine challenge treatment was without further persistent effects on these parameters, as assessed 7 days after the challenge, regardless of the interval (7 or 30 days) between the initial and challenge drug exposures. Similarly, a methamphetamine challenge treatment administered 7 days after the initial drug treatment was without further acute effect on dopamine transporter or VMAT-2 function, as assessed 1 h later. Thus, this study describes a model of resistance, possibly explained by: 1) the existence of dopaminergic neurons that are a priori refractory to deficits caused by methamphetamine; 2) the existence of dopaminergic neurons made persistently resistant consequent to a neurotoxic methamphetamine exposure; and/or 3) altered activation of post-synaptic basal ganglia systems necessary for the elaboration of methamphetamine-induced dopamine neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19326567      PMCID: PMC2768613          DOI: 10.1016/j.ejphar.2009.01.037

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  39 in total

1.  Cognitive impairment in individuals currently using methamphetamine.

Authors:  S L Simon; C Domier; J Carnell; P Brethen; R Rawson; W Ling
Journal:  Am J Addict       Date:  2000

2.  Long-term post-synaptic consequences of methamphetamine on preprotachykinin mRNA expression.

Authors:  Kamisha L Johnson-Davis; Glen R Hanson; Kristen A Keefe
Journal:  J Neurochem       Date:  2002-09       Impact factor: 5.372

3.  Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations.

Authors:  K A Hogan; R G Staal; P K Sonsalla
Journal:  J Neurochem       Date:  2000-05       Impact factor: 5.372

4.  Long-term changes in basal ganglia function after a neurotoxic regimen of methamphetamine.

Authors:  D E Chapman; G R Hanson; R P Kesner; K A Keefe
Journal:  J Pharmacol Exp Ther       Date:  2001-02       Impact factor: 4.030

5.  Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers.

Authors:  N D Volkow; L Chang; G J Wang; J S Fowler; M Leonido-Yee; D Franceschi; M J Sedler; S J Gatley; R Hitzemann; Y S Ding; J Logan; C Wong; E N Miller
Journal:  Am J Psychiatry       Date:  2001-03       Impact factor: 18.112

6.  Effect of methamphetamine neurotoxicity on learning-induced Arc mRNA expression in identified striatal efferent neurons.

Authors:  David P Daberkow; Matthew D Riedy; Raymond P Kesner; Kristen A Keefe
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

7.  Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine.

Authors:  Evan L Riddle; Matthew K Topham; John W Haycock; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2002-08-02       Impact factor: 4.432

8.  Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge.

Authors:  David S Segal; Ronald Kuczenski; Meghan L O'Neil; William P Melega; Arthur K Cho
Journal:  Neuropsychopharmacology       Date:  2003-10       Impact factor: 7.853

9.  Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence.

Authors:  Ari D Kalechstein; Thomas F Newton; Michael Green
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2003       Impact factor: 2.198

10.  Neurotoxic methamphetamine regimen severely impairs recognition memory in rats.

Authors:  Nadja Schröder; Steven J O'Dell; John F Marshall
Journal:  Synapse       Date:  2003-08       Impact factor: 2.562

View more
  13 in total

1.  Altered learning and Arc-regulated consolidation of learning in striatum by methamphetamine-induced neurotoxicity.

Authors:  Elissa D Pastuzyn; David E Chapman; Karen S Wilcox; Kristen A Keefe
Journal:  Neuropsychopharmacology       Date:  2011-11-09       Impact factor: 7.853

2.  Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.

Authors:  Lisa M McFadden; Paula L Vieira-Brock; Glen R Hanson; Annette E Fleckenstein
Journal:  Neuropharmacology       Date:  2015-01-31       Impact factor: 5.250

3.  Glial reactivity in resistance to methamphetamine-induced neurotoxicity.

Authors:  Danielle M Friend; Kristen A Keefe
Journal:  J Neurochem       Date:  2013-03-17       Impact factor: 5.372

4.  Trace amine-associated receptor 1 regulation of methamphetamine-induced neurotoxicity.

Authors:  Nicholas B Miner; Josh S Elmore; Michael H Baumann; Tamara J Phillips; Aaron Janowsky
Journal:  Neurotoxicology       Date:  2017-09-15       Impact factor: 4.294

5.  Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic Deficits.

Authors:  Paula L Vieira-Brock; Lisa M McFadden; Shannon M Nielsen; Jonathan D Ellis; Elliot T Walters; Kristen A Stout; J Michael McIntosh; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2015-09-21       Impact factor: 4.030

6.  The Neuroprotective Effect of L-Stepholidine on Methamphetamine-Induced Memory Deficits in Mice.

Authors:  Mei Zhou; Xiaokang Gong; Qin Ru; Qi Xiong; Lin Chen; Yuanren Si; Huaqiao Xiao; Chaoying Li
Journal:  Neurotox Res       Date:  2019-06-14       Impact factor: 3.911

7.  Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.

Authors:  Lisa M McFadden; Greg C Hadlock; Scott C Allen; Paula L Vieira-Brock; Kristen A Stout; Jonathan D Ellis; Amanda J Hoonakker; David M Andrenyak; Shannon M Nielsen; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2011-10-27       Impact factor: 4.030

8.  Expression and activity of nitric oxide synthase isoforms in methamphetamine-induced striatal dopamine toxicity.

Authors:  Danielle M Friend; Jong H Son; Kristen A Keefe; Ashley N Fricks-Gleason
Journal:  J Pharmacol Exp Ther       Date:  2012-12-10       Impact factor: 4.030

9.  Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration.

Authors:  Lisa M McFadden; Amanda J Hoonakker; Paula L Vieira-Brock; Kristen A Stout; Nicole M Sawada; Jonathan D Ellis; Scott C Allen; Elliot T Walters; Shannon M Nielsen; James W Gibb; Mario E Alburges; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  Synapse       Date:  2011-03-21       Impact factor: 2.562

Review 10.  Is there a role for nitric oxide in methamphetamine-induced dopamine terminal degeneration?

Authors:  Danielle M Friend; Ashley N Fricks-Gleason; Kristen A Keefe
Journal:  Neurotox Res       Date:  2013-08-06       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.